Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma
previously considered to have a poor prognosis. Large gains were made in the first decade …

Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1
and the cell cycle, disruption of DNA damage response pathways, and activation of cell …

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma of which at least a subset
arises from antigen-experienced B cells. However, what role antigen stimulation plays in its …

Background Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other
small B-cell lymphomas. The clinical and pathological characteristics of patients with this …

Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-
week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or …

To determine whether the PI3K/Akt signaling pathway is involved in the pathogenesis of
mantle cell lymphoma (MCL), we investigated the phosphorylation status of Akt and multiple …

The median survival of patients with mantle cell lymphoma (MCL) ranges from 3 to 5 years
with current chemotherapeutic regimens. A common secondary genomic alteration detected …

Abstract Phosphoinositide-3 kinase (PI3K) pathway activation contributes to mantle cell
lymphoma (MCL) pathogenesis, but early-phase studies of the PI3K p110δ inhibitor GS …

Mantle cell lymphoma (MCL) is a well‐defined lymphoid neoplasm characterized by a
proliferation of mature B lymphocytes expressing CD5 that may show a spectrum of …

Mantle cell lymphoma (MCL) is a mostly incurable malignancy arising from naive B cells
(NBCs) in the mantle zone of lymph nodes. We analyzed genomewide methylation in MCL …